Close Menu

consumer genomics

NEW YORK (GenomeWeb) –The US Food and Drug Administration has accepted for review 23andMe's 510(k) application for a single-condition health report, the consumer genomics firm informed customers.

The term 'consumer genomics' may have a catch-all ring to it, but for the time being it means ancestry testing and genetic genealogy, including for companies such as 23andMe, which built its business on relaying both personal health information and ancestral information back to c

Name: Ken Chahine Title: General manager, DNA, Ancestry.com

Name: Spencer Wells Title: Director of National Geographic's Genographic Project

When 23andMe decided to stop offering health-related tests to new customers in early December, it may have created a 2014 consumer genomics market environment defined by what company can provide the best ancestry testing and genetic genealogy experience to its customers.

While the advent of Illumina's new 24-sample BeadChip format has meant that consumer genomics companies can double or triple their throughput, some genetic genealogists have voiced concerns about what impact these new arrays might have on ancestry testing.

This article was originally posted on Nov. 27. The US Food and Drug Administration's recent letter to consumer genomics firm 23andMe could have repercussions for the microarray industry's leading vendor.

This article was originally posted on Nov. 20. 23andMe said last month that it will soon begin genotyping its customers on a new, custom-designed, higher-throughput microarray.

In an effort to raise awareness for its clinical whole-genome sequencing test, Illumina plans to expand its "Understand Your Genome" symposium program next year.

Sometime earlier this year, the millionth person ordered a direct-to-consumer genetic test. Most likely, the test was ordered for ancestry or genetic genealogy purposes. It also was likely to have been run on a microarray manufactured by Illumina.

Pages

Researchers in India plan to sequence SARS-CoV-2 isolates from around the country, according to LiveMint.

Mauro Ferrari has resigned as president of the European Research Council over its response to the COVID-19 pandemic, the Financial Times reports.

Stat News reports some health tech startups are laying off or furloughing workers.

In Genome Research this week: indels affecting microsatellites in cancer, analytical approach to find key regulatory elements, and more.